Title: New treatments for psoriasis, atopic dermatitis, HS, urticaria, including JAK inhibitors and IL-23 agents.
Authors: Togaev Akhror Turakulovich
Volume: 9
Issue: 6
Pages: 58-64
Publication Date: 2025/06/28
Abstract:
The management of chronic inflammatory dermatoses-specifically psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and chronic urticaria-has been revolutionized by targeted immunomodulatory agents. Janus kinase (JAK) inhibitors and IL-23-targeted biologics have emerged as highly effective options. This article reviews mechanisms, efficacy data, safety profiles, and emerging clinical outcomes. JAK inhibitors-including baricitinib, upadacitinib, abrocitinib, ruxolitinib, deucravacitinib, brepocitinib, and new topical agents-demonstrate strong results across AD and psoriasis. IL-23 inhibitors such as guselkumab, tildrakizumab, risankizumab, mirikizumab, and novel oral IL-23 peptides like icotrokinra and JNJ-2113 offer high psoriasis clearance rates. HS and chronic urticaria may also benefit from these modalities. The literature supports their role in personalized dermatological care, though long-term safety surveillance remains essential.